Tumor cells can modify TME leading to decreased drug delivery, penetration, exposure, and drug‐receptor engagement of antibody‐based targeted therapeutic agents.[2] TZM is a well‐known humanized monoclonal antibody that targets HER2 for the treatment of HER2‐positive tumors. This evidence concerns the gene ERBB2 and neoplasm.